Skip to main content
EDSA
NASDAQ Life Sciences

CEO Dr. Nijhawan Invests $800K in Private Placement, Increases Stake to 19.99%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.15
Mkt Cap
$55.753M
52W Low
$0.72
52W High
$20.32
52W Position info
754% above low
Off High info
70% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

EDSA has more than doubled off its 52-week low of $0.72 on light trading volume (0.3× avg).

Summary

Edesa Biotech's CEO, Dr. Pardeep Nijhawan, invested nearly $800,000 in a private placement, increasing his beneficial ownership to 19.99% and demonstrating strong confidence following recent financial and clinical updates.


Key Events · Ownership and Investor Activity · EDSA

  • CEO's Significant Investment

    Dr. Pardeep Nijhawan, CEO, purchased 153,550 common shares at $5.21 per share for an aggregate of $799,995.50 in a private placement on June 16, 2026. This investment was part of the $3.5 million private placement announced on June 11, 2026.

  • Increased Beneficial Ownership

    Dr. Nijhawan's aggregate beneficial ownership, including shares held by affiliated entities, now stands at 2,210,022 common shares, representing 19.99% of the company's outstanding common shares.

  • Prior Open Market Purchases

    The filing also disclosed several open market purchases by Dr. Nijhawan in March 2026, totaling over $130,000, with prices ranging from $2.00 to $6.5989 per share.

  • Context of Recent Events

    This significant insider investment follows a recent going concern warning (May 14, 2026) and positive exploratory clinical data for the company's drug paridiprubart (June 5, 2026).


Analysis · EDSA · Life Sciences

This Schedule 13D/A details CEO Dr. Pardeep Nijhawan's significant personal investment of nearly $800,000 in the company's recent private placement. This substantial capital injection, representing over 1.4% of the company's market capitalization, comes shortly after a going concern warning and positive clinical data, signaling strong insider confidence. His total beneficial ownership now stands at 19.99%, a high stake for an executive.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EDSA was trading at $6.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.8M. The 52-week trading range was $0.72 to $20.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EDSA - Latest Insights

EDSA
Nov 09, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.35
Real-time Price: $1.85 info
Change: -$0.4977 (-21%) info
Market Cap: $25.537M info
EDSA
Nov 09, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $1.85 info
Change: -$0.6759 (-27%) info
Market Cap: $25.537M info
EDSA
Oct 23, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.77
Real-time Price: $1.85 info
Change: -$0.9177 (-33%) info
Market Cap: $25.537M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $1.85 info
Change: -$0.7677 (-29%) info
Market Cap: $25.537M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.84
Real-time Price: $1.85 info
Change: -$0.9877 (-35%) info
Market Cap: $25.537M info